Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04477291 · ClinicalTrials.gov registry record · Phase 1
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
A Phase 1 study, sponsored by Aptose Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT04477291 is a Phase 1 study that was terminated before completion, run by Aptose Biosciences. The registered enrollment target is 45 participants.
The verdict
NCT04477291, a Phase 1 study, was terminated before completion, sponsored by Aptose Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.
Interventions
- DRUG CG-806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04477291
The ClinicalTrials.gov registry entry for NCT04477291 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptose Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CG-806 is the first listed.
NCT04477291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04477291 about?
NCT04477291 is a clinical study titled "A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS". This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineli...
What is the current status of trial NCT04477291?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-10-06. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT04477291?
The interventions under investigation include: CG-806 (DRUG).
Who is sponsoring clinical trial NCT04477291?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.